A deterministic snapshot of the global clinical-trial landscape — every figure reproducible from the ClinicaLister knowledge graph.
Registered in the past 7 days.
Trials that moved to a new overall status.
Terminations, withdrawals and suspensions — with the sponsor's stated reason.
Lack of funding and recruitment complications caused by COVID-19
As part of the protocol-specified interim pharmacokinetic (PK) evaluation in Study TMC207-C211, PK data demonstrated lower-than-anticipated bedaquiline exposure
Low enrollment
Organization lost funding
The study was terminated early due to the principal investigator's transition to another institution.
PI Request
RPD2 has been identified
Covid19 halted study
Poor accrual due to increased use of alternative neoadjuvant treatment options.
Enrollment goal not met
Protocol is with FDA review, waiting for funding to be released
22 approvals month-to-date.
| Sponsor | Drug | Approved |
|---|---|---|
| ZYDUS PHARMS | EPINEPHRINE | 2026-09-14 |
7.8% of the last year's EMA authorisations were conditional.
None authorised this period.
3 new · 0 resolved · 103 currently active.
| Newly reported shortage | Posted |
|---|---|
| Rivastigmine Film, Extended Release | 2026-09-18 |
| Melphalan Hydrochloride Injection | 2026-09-16 |
| Mesalamine Capsule, Extended Release | 2026-09-16 |
Most new trials this week.
Industry sponsors, new trials · trailing 28 days.
New links where the molecule is the studied intervention.
FDA device clearance data is current; MAUDE adverse-event and recall feeds lag ~1-2 months.
Whole-corpus totals and rankings, recomputed every week.
Monthly new registrations across ClinicalTrials.gov. Puts the weekly count in context.
By linked trials (MONDO rollup).
Among the 87,739 trials with a mapped site location — not the whole corpus.
| Sponsor | Trials |
|---|---|
| Assiut University | 4,883 |
| Cairo University | 4,853 |
| GlaxoSmithKline | 3,637 |
| Assistance Publique - Hôpitaux de Paris | 3,560 |
| National Cancer Institute (NCI) | 3,553 |
| AstraZeneca | 3,486 |
| Pfizer | 3,309 |
| Mayo Clinic | 3,249 |
| M.D. Anderson Cancer Center | 3,028 |
| Novartis Pharmaceuticals | 2,703 |
| National Taiwan University Hospital | 2,601 |
| Massachusetts General Hospital | 2,573 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 2,441 |
| Boehringer Ingelheim | 2,290 |
| University of California, San Francisco | 2,160 |
| Stanford University | 2,154 |
| Riphah International University | 2,153 |
| Merck Sharp & Dohme LLC | 2,147 |
| Hoffmann-La Roche | 2,089 |
| Eli Lilly and Company | 2,086 |
| Duke University | 2,054 |
| Memorial Sloan Kettering Cancer Center | 1,951 |
| Ain Shams University | 1,900 |
| Seoul National University Hospital | 1,893 |
| Hospices Civils de Lyon | 1,845 |
| Condition | Trials |
|---|---|
| breast cancer | 11,900 |
| obesity disorder | 9,699 |
| type 2 diabetes mellitus | 9,207 |
| chronic pain syndrome | 8,889 |
| cancer | 8,377 |
| HIV infectious disease | 8,256 |
| COVID-19 | 7,659 |
| non-small cell lung carcinoma | 6,458 |
| hypertensive disorder | 6,174 |
| diabetes mellitus | 6,169 |
| colorectal cancer | 6,089 |
| cerebrovascular disorder | 6,080 |
| coronary artery disorder | 5,985 |
| prostate cancer | 5,900 |
| depressive disorder | 5,887 |
| cardiovascular disorder | 5,638 |
| anxiety disorder | 4,990 |
| heart failure | 4,947 |
| injury | 4,540 |
| Parkinson disease | 4,481 |
| asthma | 4,454 |
| cognitive disorder | 4,229 |
| lung cancer | 4,087 |
| neuralgia | 3,912 |
| benign essential hypertension | 3,736 |
| Molecule | Trials |
|---|---|
| carboplatin | 7,241 |
| paclitaxel | 5,619 |
| isoniazid | 5,380 |
| prednisolone | 5,344 |
| cyclophosphamide | 5,144 |
| ropivacaine | 4,941 |
| dexamethasone | 4,840 |
| bevacizumab | 4,684 |
| cisplatin | 4,517 |
| lidocaine | 3,676 |
| aspirin | 3,459 |
| gemcitabine | 3,222 |
| bupivacaine | 3,192 |
| pembrolizumab | 3,029 |
| metformin | 3,014 |
| desoxycorticosterone acetate | 2,994 |
| sitagliptin and metformin hydrochloride | 2,979 |
| rituximab | 2,964 |
| meprednisone | 2,850 |
| sitagliptin metformin hydrochloride | 2,791 |
| dapagliflozin metformin hydrochloride | 2,788 |
| linagliptin and metformin hydrochloride | 2,778 |
| docetaxel | 2,776 |
| fluorouracil | 2,754 |
| alogliptin and metformin hydrochloride | 2,720 |
Standing competitive & regulatory landscape — who is developing what, at which stage, and which drugs are about to lose exclusivity.
Active trials by the most prolific industry sponsors, split by phase.
| Phase 1 | Phase 2 | Phase 3 | |
|---|---|---|---|
| GlaxoSmithKline | 1,096 | 862 | 900 |
| AstraZeneca | 1,023 | 552 | 810 |
| Pfizer | 1,177 | 710 | 666 |
| Novartis Pharmaceuticals | 512 | 840 | 738 |
| Boehringer Ingelheim | 1,073 | 321 | 400 |
| Merck Sharp & Dohme LLC | 702 | 552 | 742 |
| Hoffmann-La Roche | 494 | 483 | 572 |
| Eli Lilly and Company | 836 | 536 | 550 |
FDA drugs whose exclusivity expires soon (distinct substances).
| Drug (losing exclusivity < 6mo) | Expires |
|---|---|
| Phentolamine Mesylate | 2026-09-25 |
| Atogepant | 2026-09-28 |
| Miglustat | 2026-09-28 |
| Technetium Tc-99m Labeled Carbon | 2026-09-29 |
| Patiromer Sorbitex Calcium | 2026-10-02 |
| Dexamethasone | 2026-10-03 |
| Risdiplam | 2026-10-03 |
| Afamelanotide | 2026-10-08 |
| Binimetinib | 2026-10-11 |
| Acetaminophen; Ibuprofen Sodium | 2026-10-17 |
| Pilocarpine Hydrochloride | 2026-10-17 |
| Tenapanor Hydrochloride | 2026-10-17 |
| Treprostinil Diolamine | 2026-10-18 |
| Edoxaban Tosylate | 2026-10-18 |
| Adapalene; Benzoyl Peroxide; Clindamycin Phosphate | 2026-10-20 |
FDA drugs carrying each designation.
Molecules most often used as the comparator arm (the standard to beat).
Every figure is a deterministic SQL aggregate over the ClinicaLister knowledge graph as of the report date. No figure is AI-generated or estimated; each is reproducible and traceable to its public source.
Sources: ClinicalTrials.gov · EU CTIS · openFDA (drugs, devices, shortages) · EMA · MONDO disease ontology · GSRS · GUDID · Europe PMC / PubMed
Every figure above is a deterministic aggregate over the ClinicaLister knowledge graph — and one click deep in the product, with a source behind each claim.
Machine-readable: download this edition as JSON above, or query the full archive programmatically via the public get_public_report_snapshots endpoint.